OKUR Stock Overview
A clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
OnKure Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.02 |
| 52 Week High | US$20.00 |
| 52 Week Low | US$14.12 |
| Beta | 0 |
| 11 Month Change | -11.80% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -19.46% |
Recent News & Updates
Shareholder Returns
| OKUR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.4% | 4.0% | 2.0% |
| 1Y | n/a | 18.0% | 32.4% |
Return vs Industry: Insufficient data to determine how OKUR performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how OKUR performed against the US Market.
Price Volatility
| OKUR volatility | |
|---|---|
| OKUR Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OKUR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine OKUR's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 50 | Nick Saccomano | onkuretherapeutics.com |
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado.
OnKure Therapeutics, Inc. Fundamentals Summary
| OKUR fundamental statistics | |
|---|---|
| Market cap | US$206.49m |
| Earnings (TTM) | -US$44.69m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.5x
P/E RatioIs OKUR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OKUR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$44.69m |
| Earnings | -US$44.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.35 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -114.6% |
How did OKUR perform over the long term?
See historical performance and comparison